NKARTA INC. - COMMON
2.5650
26-November-24 14:30:07
15 minutes delayed
Stocks
-0.0250
-0.97%
Today's range
2.5300 - 2.6700
ISIN
N/A
Source
NASDAQ
-
Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs
07 Oct 2021 16:01:00 By Nasdaq GlobeNewswire
-
Nkarta to Present Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting
01 Oct 2021 08:08:00 By Nasdaq GlobeNewswire
-
Nkarta to Participate at Upcoming Investor Conference
14 Sep 2021 08:32:00 By Nasdaq GlobeNewswire
-
Nkarta Reports Second Quarter 2021 Financial Results and Business Progress
12 Aug 2021 16:02:00 By Nasdaq GlobeNewswire
-
Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters
14 Jul 2021 07:00:00 By Nasdaq GlobeNewswire
-
Nkarta to Present at Upcoming Investor Conference
16 Jun 2021 07:00:00 By Nasdaq GlobeNewswire
-
Nkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term
14 Jun 2021 07:01:00 By Nasdaq GlobeNewswire
-
Nkarta Announces June 2021 Investor Conference Schedule
25 May 2021 07:30:00 By Nasdaq GlobeNewswire
-
Nkarta Reports First Quarter 2021 Financial Results and Business Progress
13 May 2021 16:02:00 By Nasdaq GlobeNewswire
-
28 Apr 2021 08:02:00 By Nasdaq GlobeNewswire
-
Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress
25 Mar 2021 16:03:00 By Nasdaq GlobeNewswire
-
Nkarta Announces February and March 2021 Investor Conference Schedule
17 Feb 2021 16:03:00 By Nasdaq GlobeNewswire